Drug Stores and Mass Merchandisers to Sell Unique Back and Other Pain
FREDERICK, Md., Feb. 5 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that it has signed a sales, marketing and distribution agreement with Locin Industries, Ltd, Vancouver, Canada.
"Locin Industries Ltd. is a leading Canadian sales and marketing distributor of natural health products, medical devices, and health and beauty aids. Locin has over 30 years of experience in bringing new brands to market. Health Canada has approved ActiPatch for over-the-counter sales for the relief of pain in muscosketal complaints. This agreement will usher in a new era for biophysics medicine," said Andrew Whelan, President of BioElectronics.
"ActiPatch is a unique drug free, anti inflammatory therapy, which will retail in Canada at market disruptive prices providing therapy for less than $1.50 per day. We are confident and committed to making ActiPatch a major Canadian brand," said Brad Collins, Vice President of Sales & Marketing for Locin Industries.
For more information visit http://www.locin.com/.
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com.
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
|SOURCE BioElectronics Corporation|
Copyright©2008 PR Newswire.
All rights reserved